VCL-HM01

VCL-HM01 is an experimental therapeutic DNA vaccine developed by Vical Incorporated for the treatment of genital herpes caused by herpes simplex virus type 2 (HSV-2). It is a bivalent vaccine consisting of two DNA plasmids that encode the HSV-2 glycoprotein D (gD) and the tegument protein UL46. VCL-HM01 was designed to stimulate both humoral and cellular immune responses to reduce viral shedding and the frequency of lesion recurrences in HSV-2-seropositive individuals. In clinical trials, VCL-HM01 served as the non-adjuvanted counterpart to VCL-HB01 (which includes the Vaxfectin adjuvant) to evaluate the specific contribution of the adjuvant to the vaccine's safety and immunogenicity profile. Development of the HSV-2 vaccine program was discontinued by Vical following the failure of the lead candidate, VCL-HB01, to meet its primary endpoint in a Phase 2 clinical trial in 2018.

Other names

HSV-2 therapeutic DNA vaccineHSV2 therapeutic DNA vaccineHSV 2 therapeutic DNA vaccine